Company Description
NanoVibronix, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target wound healing and pain therapy and can be administered at home, without the assistance of medical professionals.
Its product portfolio includes UroShield, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use.
The company also offers UroShield Ultra, which is designed to prevent bacterial colonization and biofilm formation in urinary catheters; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm and joint contractures.
In addition, it provides PainShield MD, a single patch-based therapeutic ultrasound technology to treat pain, muscle spasm and joint contractures; PainShield Plus, a dual patch-based therapeutic ultrasound technology; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing.
The company sells its products directly to patients, as well as through distributor agreements in the United States, Europe, Australia, Israel, New Zealand, and internationally.
NanoVibronix, Inc. was incorporated in 2003 and is based in Tyler, Texas.
| Country | United States |
| Founded | 2003 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 31 |
| CEO | Brian Murphy |
Contact Details
Address: 969 Pruitt Ave Tyler, Texas 77569 United States | |
| Phone | 914 233 3004 |
| Website | nanovibronix.com |
Stock Details
| Ticker Symbol | NAOV |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001326706 |
| CUSIP Number | 63008J108 |
| ISIN Number | US63008J6038 |
| SIC Code | 3842 |
Key Executives
| Name | Position |
|---|---|
| Brian M. Murphy | Chief Executive Officer and Director |
| Stephen R. Brown CPA | Chief Financial Officer |
| Dr. Harold Jacob M.D. | Chief Medical Officer |
| Lindsey Harrison | Vice President of Sales |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 29, 2025 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Apr 22, 2025 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Apr 11, 2025 | 8-K | Current Report |
| Apr 3, 2025 | 8-K | Current Report |
| Mar 31, 2025 | 10-K | Annual Report |
| Mar 14, 2025 | 8-K | Current Report |
| Mar 12, 2025 | 8-K | Current Report |
| Feb 25, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 14, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |